NEW YORK, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst breakfast on Friday, October 31, 2014 from 8:00 am-9:30 am Eastern Time in New York City. The meeting will feature discussions by two retinal disease experts, K. Bailey Freund, M.D., and Ohr's Chief Medical Officer, Jason S. Slakter, MD.
Dr. Freund specializes in all retinal disorders and has been a principal investigator in several pivotal trials of novel treatments for retinal diseases, including macular degeneration, diabetic retinopathy, and retinal vascular and inflammatory diseases. He is a Clinical Associate Professor of Ophthalmology at the NYU School of Medicine and practices at New York Presbyterian Hospital, Manhattan Eye Ear & Throat Institute, and Vitreous-Retina-Macula Consultants of NY, the largest retina practice in the New York Metropolitan area.
Dr. Slakter, who currently serves as the Chief Medical Officer at Ohr, is an internationally recognized retinal and macular disease specialist and has played a major role in developing treatments for age-related macular degeneration, retinal vascular disease, diabetic retinopathy, and central serous chorioretinopathy. He is a Clinical Professor of Ophthalmology at NYU School of Medicine and practices at Vitreous-Retina-Macula Consultants of NY.
Ohr company management will also be on hand to answer questions during a Q&A session.
A live webcast of the event will be available at http://lifesci.rampard.com/20141031/ and will also be accessible through the Investors section of the Company's website at www.ohrpharmaceutical.com. The event is intended for institutional investors and sell-side analysts only. To RSVP for the event, please contact Veronica Molina at 212-915-2567 or via e-mail at vmolina@lifesciadvisors.com.
About Squalamine Eye Drops (OHR-102)
Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, which counteracts multiple growth factors and pathways implicated in the angiogenic process, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF). Ohr Pharmaceutical has developed a novel eye drop formulation of Squalamine (OHR-102) for the treatment of wet AMD, designed for convenient, patient self-administration, which may provide clinical utility for this patient population and other back-of-the-eye disorders. In May 2012, the Squalamine eye drop program was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). A Phase II randomized, double masked, placebo-controlled study (IMPACT Study) to evaluate the efficacy and safety of Squalamine eye drops for the treatment of wet AMD is ongoing and has completed enrollment. Interim data released in June 2014 demonstrated benefit in visual function versus placebo across multiple standard parameters. Three additional investigator sponsored trials (IST) are evaluating Squalamine eye drops for the treatment of proliferative diabetic retinopathy, retinal vein occlusion, and diabetic macular edema.
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The lead sustained release program in glaucoma is proceeding under a collaboration with a large global pharmaceutical company. Additional information on the company may be found at www.ohrpharmaceutical.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.
Lucentis® is a registered trademark of Genentech, Inc.